

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags  
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition  
NEWS 4 AUG 13 CA/Caplus enhanced with additional kind codes for granted patents  
NEWS 5 AUG 20 CA/Caplus enhanced with CAS indexing in pre-1907 records  
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB  
NEWS 7 AUG 27 USPATOLD now available on STN  
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data  
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index  
NEWS 10 SEP 13 FORIS renamed to SOFIS  
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency  
NEWS 12 SEP 17 CA/Caplus enhanced with printed CA page images from 1967-1998  
NEWS 13 SEP 17 Caplus coverage extended to include traditional medicine patents  
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 15 OCT 02 CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt  
NEWS 16 OCT 19 BEILSTEIN updated with new compounds  
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced  
NEWS 18 NOV 19 WPIX enhanced with XML display format  
NEWS 19 NOV 30 ICSD reloaded with enhancements  
NEWS 20 DEC 04 LINPADOCDB now available on STN  
NEWS 21 DEC 14 BEILSTEIN pricing structure to change  
NEWS 22 DEC 17 USPATOLD added to additional database clusters  
NEWS 23 DEC 17 IMSDRUGCONF removed from database clusters and STN  
NEWS 24 DEC 17 DGENE now includes more than 10 million sequences  
NEWS 25 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment  
NEWS 26 DEC 17 MEDLINE and LMEEDLINE updated with 2008 MeSH vocabulary  
NEWS 27 DEC 17 CA/Caplus enhanced with new custom IPC display formats  
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD  
NEWS 29 JAN 02 STN pricing information for 2008 now available  
  
NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:59:54 ON 14 JAN 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:00:04 ON 14 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JAN 2008 HIGHEST RN 960495-31-2

DICTIONARY FILE UPDATES: 13 JAN 2008 HIGHEST RN 960495-31-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152a.str



```

chain nodes :
16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
4-16 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-16 5-6 5-7 6-9 7-8 8-9
exact bonds :
9-10
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:00:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 110 TO ITERATE

100.0% PROCESSED 110 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1571 TO 2829

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:00:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2241 TO ITERATE

100.0% PROCESSED 2241 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 339566-10-8 REGISTRY


ED Entered STN: 06 Jun 2001

CN Imidazo[1,2-b]isoquinoline-5,10-dione, 3-phenyl- (CA INDEX NAME)

MF C17 H10 N2 O2

SR Reaction Database



LC STN Files: CASREACT



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152b.str



```

chain nodes :
16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
4-16 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-16 5-6 5-7 6-9 7-8 8-9 9-10
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

```

G1:CH,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



G1 CH,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 17:02:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 264 TO ITERATE

100.0% PROCESSED 264 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 4306 TO 6254

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 full

FULL SEARCH INITIATED 17:02:52 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5294 TO ITERATE



100.0% PROCESSED 5294 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

L6 0 SEA SSS FUL L4

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152c.str



chain nodes :

16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

4-16 9-10

ring bonds :



1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-15 11-12 12-13 13-14  
 14-15  
 exact/norm bonds :  
 1-2 1-6 2-3 3-4 4-5 4-16 5-6 5-7 6-9 7-8 8-9 9-10  
 normalized bonds :  
 10-11 10-15 11-12 12-13 13-14 14-15

G1:CH,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS

L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR



G1 CH,N

Structure attributes must be viewed using STN Express query preparation.

=> s 17

SAMPLE SEARCH INITIATED 17:06:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 216 TO ITERATE

100.0% PROCESSED 216 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3439 TO 5201

PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=> s l7 full  
FULL SEARCH INITIATED 17:06:19 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 4324 TO ITERATE

100.0% PROCESSED 4324 ITERATIONS 35 ANSWERS  
SEARCH TIME: 00.00.01

L9 35 SEA SSS FUL L7

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 540.76 540.97

FILE 'CAPLUS' ENTERED AT 17:06:26 ON 14 JAN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jan 2008 VOL 148 ISS 3  
FILE LAST UPDATED: 13 Jan 2008 (20080113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l9  
L10 3 L9

=> s l9 and pd<=20021106  
3 L9  
22840688 PD<=20021106  
(PD<=20021106)  
L11 0 L9 AND PD<=20021106

=> d l10 1-3 ibib abs hitstr


L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:128501 CAPLUS


DOCUMENT NUMBER: 144:343043

TITLE: Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as  $\alpha_2/\alpha_3$  subtype selective GABAA agonists for the treatment of anxiety  
AUTHOR(S): Goodacre, Simon C.; Hallett, David J.; Carling, Robert W.; Castro, Jose L.; Reynolds, David S.; Pike, Andrew;


Wafford, Keith A.; Newman, Robert; Atack, John R.; Street, Leslie J.  
 CORPORATE SOURCE: Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Harlow, Essex, CM20 2QR, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1582-1585  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 144:343043  
 AB Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones are high affinity GABAA agonists. Compound 16d has good oral bioavailability in rat, functional selectivity for the GABAA $\alpha$ 2 and  $\alpha$ 3-subtypes and is anxiolytic in a conditioned animal model of anxiety with minimal sedation observed at full BZ binding site occupancy.  
 IT 689296-91-1P 689297-04-9P 689297-17-4P 689297-19-6P 689297-55-0P 798570-60-2P 881743-79-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (a2/a3 subtype selective GABAA agonists for the treatment of anxiety)  
 RN 689296-91-1 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-04-9 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 689297-17-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)




RN 689297-19-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 689297-55-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-d][1,2,4]triazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 798570-60-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(3,4-dihydro-3-methyl-4-oxoimidazo[2,1-f][1,2,4]triazin-7-yl)-2',4-difluoro- (CA INDEX NAME)




RN 881743-79-9 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




IT 881743-74-4  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 ( $\alpha 2/\alpha 3$  subtype selective GABAA agonists for the treatment  
 of anxiety)  
 RN 881743-74-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-methyl-3-phenyl- (CA INDEX NAME)




IT 689297-65-2P 689297-98-1P 918544-48-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 ( $\alpha 2/\alpha 3$  subtype selective GABAA agonists for the treatment  
 of anxiety)  
 RN 689297-65-2 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-  
 3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-98-1 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-  
 3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 918544-48-6 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:1019775 CAPLUS  
 DOCUMENT NUMBER: 142:6561  
 TITLE: Preparation of imidazotriazinones as ligands for GABA receptors for treating anxiety, convulsions or cognitive disorders  
 INVENTOR(S): Goodacre, Simon Charles  
 PATENT ASSIGNEE(S): Merck Sharp & Dohme Ltd., UK  
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004235844	A1	20041125	US 2004-848461	20040518
US 6914060	B2	20050705		
PRIORITY APPLN. INFO.:			GB 2003-11859	A 20030522
OTHER SOURCE(S):	MARPAT	142:6561		
GI				



AB The title compds. [I; X1 = H, halo, alkyl, CF3, alkoxy; X2 = H, halo; Y = a bond, O, NH; Z = (un)substituted (hetero)aryl; R1 = alkyl, heterocyclyl, CF3, etc.], being ligands for GABAA receptors and accordingly of benefit in the therapy of deleterious neurol. disorders, were prepared E.g., a 5-step synthesis of 4,2'-difluoro-5'-(3-methyl-4-oxo-3,4-dihydroimidazo[2,1-f][1,2,4]triazin-7-yl)biphenyl-2-carbonitrile, starting from 4-methyl-3-thiosemicarbazide, which showed Ki of  $\leq 100$  nM for displacement of [3H]-flumazenil from the  $\alpha 2$  and/or  $\alpha 3$  and/or  $\alpha 5$  subunit of the human GABAA receptor, was given. The pharmaceutical composition comprising the compound I is disclosed.


IT 798570-60-2P, 4,2'-Difluoro-5'-(3-methyl-4-oxo-3,4-dihydroimidazo[2,1-f][1,2,4]triazin-7-yl)biphenyl-2-carbonitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazotriazinones as ligands for GABA receptors)

RN 798570-60-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(3,4-dihydro-3-methyl-4-oxoimidazo[2,1-f][1,2,4]triazin-7-yl)-2',4'-difluoro- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:412949 CAPLUS

DOCUMENT NUMBER: 140:406827

TITLE: Preparation of imidazopyrazinone and imidazotriazinone derivatives as GABAA receptor ligands

INVENTOR(S): Carling, William Robert; Castro Pineiro, Jose Luis; Goodacre, Simon Charles; Hallett, David James; Street, Leslie Joseph

PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK

SOURCE: PCT Int. Appl., 49 pp.



CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041826	A1	20040521	WO 2003-GB4685	20031029
WO 2004041826	A8	20050630		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003278377	A1	20040607	AU 2003-278377	20031029
US 2006014744	A1	20060119	US 2005-533152	20050427
PRIORITY APPLN. INFO.:			GB 2002-25923	A 20021106
			GB 2003-2529	A 20030204
			GB 2003-4415	A 20030226
			GB 2003-13646	A 20030612
			WO 2003-GB4685	W 20031029
OTHER SOURCE(S):		MARPAT 140:406827		
GI				



AB The title compds. I [-U-V- = -CH=CH-, -CH2-CH2-, -N=CH-, or -CH=N-; X1 = H, halo, alkyl, CF3, or alkoxy; X2 = H or halo; Y = a bond, O, -NH-, -OCH2-, Z = (substituted)aryl or (substituted)heteroaryl; R1 = alkyl, heterocyclyl, CF3, -SO2Ra, -SO2NRaRb, -CORa, or -CONRaRb; Ra, Rb = H,



alkyl, heterocyclyl] were prepared as as GABAA receptor ligands for treating and/or preventing anxiety, convulsions or a cognitive disorder. Thus, reaction of 3-bromo-8-methoxyimidazo[1,2-a]pyrazine (preparation given) and 2'-fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile following by heating in HBr and methylation afforded compound II.


IT 689296-91-1P 689296-94-4P 689296-98-8P  
 689297-01-6P 689297-04-9P 689297-07-2P  
 689297-10-7P 689297-13-0P 689297-15-2P  
 689297-17-4P 689297-19-6P 689297-21-0P  
 689297-23-2P 689297-25-4P 689297-27-6P  
 689297-29-8P 689297-31-2P 689297-33-4P  
 689297-35-6P 689297-37-8P 689297-39-0P  
 689297-41-4P 689297-43-6P 689297-45-8P  
 689297-47-0P 689297-49-2P 689297-51-6P  
 689297-53-8P 689297-55-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)


RN 689296-91-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689296-94-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689296-98-8 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)




RN 689297-01-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2'-fluoro- (CA INDEX NAME)




RN 689297-04-9 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 689297-07-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-4'-fluoro- (CA INDEX NAME)




RN 689297-10-7 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-5'-fluoro- (CA INDEX NAME)




RN 689297-13-0 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2,2'-difluoro- (CA INDEX NAME)




RN 689297-15-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-ethyl-3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]- (CA INDEX NAME)




RN 689297-17-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6'-difluoro- (CA INDEX NAME)




RN 689297-19-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4'-difluoro- (CA INDEX NAME)




RN 689297-21-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-23-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-(1-methylethyl)-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-25-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)




RN 689297-27-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-29-8 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-31-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-33-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)




RN 689297-35-6 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3-chloro-5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689297-37-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)




RN 689297-39-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)




RN 689297-41-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)]- (CA INDEX NAME)




RN 689297-43-6 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 2',5-difluoro-5'-[(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)]- (CA INDEX NAME)




RN 689297-45-8 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 2'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)




RN 689297-47-0 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-49-2 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',5-difluoro- (CA INDEX NAME)




RN 689297-51-6 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)




RN 689297-53-8 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[5,6,7,8-tetrahydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)



RN 689297-55-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-d][1,2,4]triazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




IT 689297-65-2P 689297-98-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)

RN 689297-65-2 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-98-1 CAPLUS



CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 02	CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	3	OCT 19	BEILSTEIN updated with new compounds
NEWS	4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	5	NOV 19	WPIX enhanced with XML display format
NEWS	6	NOV 30	ICSD reloaded with enhancements
NEWS	7	DEC 04	LINPADOODB now available on STN
NEWS	8	DEC 14	BEILSTEIN pricing structure to change
NEWS	9	DEC 17	USPATOLD added to additional database clusters
NEWS	10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC 17	DGENE now includes more than 10 million sequences
NEWS	12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13	DEC 17	MEDLINE and LMEEDLINE updated with 2008 MeSH vocabulary
NEWS	14	DEC 17	CA/CAPLUS enhanced with new custom IPC display formats
NEWS	15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	16	JAN 02	STN pricing information for 2008 now available
NEWS	17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	19	JAN 28	MARPAT searching enhanced
NEWS	20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	22	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	23	FEB 08	STN Express, Version 8.3, now available
NEWS	24	FEB 20	PCI now available as a replacement to DPCI

NEWS 25 FEB 25 IFIREF reloaded with enhancements  
NEWS 26 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 27 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:38:55 ON 12 MAR 2008

=> gistry  
GISTRY IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:39:04 ON 12 MAR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2008 HIGHEST RN 1007457-12-6  
DICTIONARY FILE UPDATES: 11 MAR 2008 HIGHEST RN 1007457-12-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10 series\10533152\10533152d.str



chain nodes :

10

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16

chain bonds :

4-10 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15  
15-16

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 8-9

exact bonds :

9-11

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS


11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:39:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      308 TO ITERATE

100.0% PROCESSED      308 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   5108 TO    7212
PROJECTED ANSWERS:      0 TO      0
```

```
L2      0 SEA SSS SAM L1
```


```
=> s l1 full
FULL SEARCH INITIATED 16:39:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    6346 TO ITERATE

100.0% PROCESSED    6346 ITERATIONS    45 ANSWERS
SEARCH TIME: 00.00.01
```

```
L3      45 SEA SSS FUL L1
```

```
=> d scan
```

```
L3      45 ANSWERS  REGISTRY  COPYRIGHT 2008 ACS on STN
IN      [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-
MF      alpyrazin-3-yl)-2',6'-difluoro-
        C20 H12 F2 N4 O
```



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
178.82	179.03

FILE 'CAPLUS' ENTERED AT 16:40:09 ON 12 MAR 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2008 VOL 148 ISS 11  
 FILE LAST UPDATED: 11 Mar 2008 (20080311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 8 L3

=> d 14 1-8 ibib abs hitstr

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:966023 CAPLUS

DOCUMENT NUMBER: 147:322989

TITLE: Preparation of bicyclic heteroaryl derivatives as cannabinoid receptor modulators

INVENTOR(S): Kundo, Mrinalkanti; Khairatkar-Joshi, Neelima; Nadkarni, Suhas M.; Pansare, Rameswar Madhavrao; Karnik, Pallavi V.

PATENT ASSIGNEE(S): Glenmark Pharmaceuticals S.A., Switz.



SOURCE: PCT Int. Appl., 172pp., which  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007096764	A2	20070830	WO 2007-1B459	20070226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:  
 IN 2006-MU275 A 20060227  
 US 2006-781055P P 20060310  
 IN 2006-MU1146 A 20060718  
 US 2006-821475P P 20060804  
 IN 2006-MU2088 A 20061220


OTHER SOURCE(S): MARPAT 147:322989  
 GI



AB Title compds. represented by the formula I [wherein X1 = CR, X2 = N or X1 = N, X2 = CR; R, R1a, R1b, R2, R3 = independently H, cyano, formyl, etc.; m = 1-5; n = 1-5; and analogs, N-oxides, tautomers, regioisomers, prodrugs, polymorphs, and pharmaceutically acceptable salts or solvates thereof] were prepared as cannabinoid receptor modulators. For example, reaction of (5-phenylpyrazin-2-yl)amine with 2-bromo-1-(4-chlorophenyl)-2-phenylethanone (preparation given) gave II. I were tested in in vitro for rat CB1 receptor binding using brain membrane and hCB1-CHO membranes, in vitro protocol for rat CB2 receptor binding using spleen membrane and hCB2-CHO

membranes. Thus, I and their pharmaceutical compns. are useful for the treatment of diseases, conditions and/or disorders modulated by a cannabinoid receptor, such as pain, neurodegenerative disorders, eating disorders, weight loss or control, obesity, smoking cessation, alc. dependency, depression, and attention deficit hyperactivity disorder.

IT 947592-97-4P, 2,3-Bis(4-chlorophenyl)-6-(3-chlorophenyl)-8-methoxyimidazo[1,2-a]pyrazine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazo[1,2-a]pyrazine and imidazo[1,2-a]pyrimidine derivs. as cannabinoid receptor modulators)  
 RN 947592-97-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 6-(3-chlorophenyl)-2,3-bis(4-chlorophenyl)-8-methoxy- (CA INDEX NAME)



L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:507532 CAPLUS  
 DOCUMENT NUMBER: 146:501082  
 TITLE: Imidazopyrazine compounds and their methods for inhibiting protein kinases, preparation, pharmaceutical compositions and use in the treatment of protein kinase-associated diseases  
 INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Parry, David A.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga Adulla P.; Siddiqui, M. Arshad; Tadikonda, Praveen K.  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: U.S. Pat. Appl. Publ., 346pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007105864	A1	20070510	US 2006-598188	20061108
WO 2007056468	A1	20070518	WO 2006-US43512	20061108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:



US 2005-735610P

P 20051110

OTHER SOURCE(S):

MARPAT 146:501082

GI



AB The invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, CCheckpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compds. of formula I and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compds. Compds. of formula I wherein R is H, halo, (un)substituted (hetero)aryl, (un)substituted cycloalkyl, (un)substituted arylalkyl, (un)substituted heterocyclyl, etc.; R1 is H, halo, and alkyl; R2 is alkyl, (un)substituted (hetero)aryl(alkyl), alkenyl, alkynyl, etc.; R3 is H, (un)substituted (hetero)aryl(alkyl), (un)substituted heterocyclyl(alkyl), (un)substituted (hetero)cycloalkyl, etc.; and their pharmaceutically acceptable salts, solvates, esters, and prodrugs thereof are claimed. Example compound II was prepared by amination of 3-(1-methylpyrazol-4-yl)-7-methylsulfonylimidazo[1,2-a]pyrazine with 3-(methylsulfonyl)aniline. All the invention compds. were evaluated for their protein kinase inhibitory activity (data given).

IT 887476-05-3P 936360-38-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyrazine compds. as protein kinase inhibitors useful in treatment and prevention of protein kinase-associated diseases)

RN 887476-05-3 CAPLUS


CN Benzenamine, 4-(6-bromo-8-methoxyimidazo[1,2-a]pyrazin-3-yl)-N,N-dimethyl- (CA INDEX NAME)





RN 936360-38-2 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-bromo-8-methoxy-3-(3-methyl-1H-indazol-5-yl)-  
(CA INDEX NAME)



L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:463553 CAPLUS

DOCUMENT NUMBER: 144:488677

TITLE: Preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M. Arshad

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 47,524.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006106023	A1	20060518	US 2005-272392	20051110
US 2004063715	A1	20040401	US 2003-665005	20030919
US 6919341	B2	20050719		
US 2005130980	A1	20050616	US 2005-47524	20050131
WO 2007058873	A2	20070524	WO 2006-US43592	20061108
WO 2007058873	A3	20070719		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

AU 2007200401  
PRIORITY APPLN. INFO.:



A1 20070222

AU 2007-200401  
US 2002-412997P  
US 2003-665005  
US 2005-47524  
AU 2003-272476  
US 2005-272392

20070131  
P 20020923  
A3 20030919  
A2 20050131  
A3 20030919  
A 20051110

OTHER SOURCE(S):  
GI

MARPAT 144:488677



AB In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical

formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC50 value of 22.5  $\mu$ M.


IT 887476-05-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 887476-05-3 CAPLUS

CN Benzenamine, 4-(6-bromo-8-methoxyimidazo[1,2-a]pyrazin-3-yl)-N,N-dimethyl-  
(CA INDEX NAME)



L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:128501 CAPLUS

DOCUMENT NUMBER: 144:343043

TITLE: Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-

d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as  $\alpha 2/\alpha 3$  subtype selective GABAA agonists for the treatment of anxiety  
AUTHOR(S): Goodacre, Simon C.; Hallett, David J.; Carling, Robert W.; Castro, Jose L.; Reynolds, David S.; Pike, Andrew; Wafford, Keith A.; Newman, Robert; Atack, John R.; Street, Leslie J.

CORPORATE SOURCE: Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Harlow, Essex, CM20 2QR, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1582-1585

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:343043

AB Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones are high affinity GABAA agonists. Compound 16d has good oral bioavailability in rat, functional selectivity for the GABAA $\alpha 2$  and  $\alpha 3$ -subtypes and is anxiolytic in a conditioned animal model of anxiety with minimal sedation observed at full BZ binding site occupancy.

IT 689296-91-1P 689297-04-9P 689297-17-4P


689297-19-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

( $\alpha 2/\alpha 3$  subtype selective GABAA agonists for the treatment of anxiety)


RN 689296-91-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689297-04-9 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



RN 689297-17-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)




RN 689297-19-6 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




IT 881743-74-4  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (α2/α3 subtype selective GABAA agonists for the treatment  
 of anxiety)

RN 881743-74-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-methyl-3-phenyl- (CA INDEX NAME)




IT 689297-63-0P 689297-65-2P 689297-98-1P  
 918544-48-6P 918545-23-0P 918545-44-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (α2/α3 subtype selective GABAA agonists for the treatment  
 of anxiety)  
 RN 689297-63-0 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)




RN 689297-65-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689297-98-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 918544-48-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)




RN 918545-23-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 918545-44-5 CAPLUS  
 CN [1,1'-Biphenyl]-2-carbonitrile, 2',6-difluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)






REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:346791 CAPLUS  
 DOCUMENT NUMBER: 142:411376  
 TITLE: A preparation of imidazopyrazine derivatives, useful as antiarrhythmics  
 INVENTOR(S): Plouvier, Bertrand M. C.; Fedida, David; Beatch, Gregory N.; Chou, Doug Ta Hung; Yifru, Aregahegn S.; Jung, Grace  
 PATENT ASSIGNEE(S): Cardiome Pharma Corporation, Can.  
 SOURCE: PCT Int. Appl., 100 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034837	A2	20050421	WO 2004-IB3601	20041008
WO 2005034837	A3	20050714		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-510010P P 20031008  
 OTHER SOURCE(S): CASREACT 142:411376; MARPAT 142:411376

GI



AB The invention relates to a preparation of imidazopyrazine derivs. of formula I [wherein: R1, R2, R3, and R4 are independently selected from H, Br, Cl, F, NO2, CHF2, or (cyclo)alkyl, etc.; R5 is a substituted alkyl], useful as antiarrhythmics. For instance, imidazopyrazinone derivative II [IC50 (μM), ion-channels: Kv1.5 - 4.8, hERG - 100, H1Na - 340, Kv2.1 - 60] was prepared via amination of 1-phenyl-1-cyclopropylmethanol by imidazopyrazine derivative III with a yield of 42%.


IT 850406-59-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyrazine derivs. useful as antiarrhythmics)

RN 850406-59-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 5-chloro-7-[(2-nitrophenyl)methyl]-3-phenyl- (CA INDEX NAME)



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on SIN

ACCESSION NUMBER: 2004:412949 CAPLUS

DOCUMENT NUMBER: 140:406827

TITLE: Preparation of imidazopyrazinone and imidazotriazinone derivatives as GABAA receptor ligands  
 INVENTOR(S): Carling, William Robert; Castro Pineiro, Jose Luis; Goodacre, Simon Charles; Hallett, David James; Street, Leslie Joseph



PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK

SOURCE: PCT Int. Appl., 49 pp.

DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041826	A1	20040521	WO 2003-GB4685	20031029
WO 2004041826	A8	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003278377	A1	20040607	AU 2003-278377	20031029
US 2006014744	A1	20060119	US 2005-533152	20050427
PRIORITY APPLN. INFO.:			GB 2002-25923	A 20021106
			GB 2003-2529	A 20030204
			GB 2003-4415	A 20030226
			GB 2003-13646	A 20030612
			WO 2003-GB4685	W 20031029

OTHER SOURCE(S): MARPAT 140:406827  
 GI



AB The title compds. I [-U-V- = -CH=CH-, -CH2-CH2-, -N=CH-, or -CH=N-; X1 =



H, halo, alkyl, CF<sub>3</sub>, or alkoxy; X<sub>2</sub> = H or halo; Y = a bond, O, -NH-, -OCH<sub>2</sub>-; Z = (substituted)aryl or (substituted)heteroaryl; R<sub>1</sub> = alkyl, heterocyclyl, CF<sub>3</sub>, -SO<sub>2</sub>R<sub>a</sub>, -SO<sub>2</sub>NR<sub>a</sub>R<sub>b</sub>, -COR<sub>a</sub>, or -CONR<sub>a</sub>R<sub>b</sub>; R<sub>a</sub>, R<sub>b</sub> = H, alkyl, heterocyclyl were prepared as as GABAA receptor ligands for treating and/or preventing anxiety, convulsions or a cognitive disorder. Thus, reaction of 3-bromo-8-methoxyimidazo[1,2-a]pyrazine (preparation given) and 2'-fluoro-5'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-2-carbonitrile following by heating in HBr and methylation afforded compound II.


IT 689296-91-1P 689296-94-4P 689296-98-8P  
 689297-01-6P 689297-04-9P 689297-07-2P  
 689297-10-7P 689297-13-0P 689297-15-2P  
 689297-17-4P 689297-19-6P 689297-21-0P  
 689297-23-2P 689297-25-4P 689297-27-6P  
 689297-29-8P 689297-31-2P 689297-33-4P  
 689297-35-6P 689297-37-8P 689297-39-0P  
 689297-41-4P 689297-43-6P 689297-45-8P  
 689297-47-0P 689297-49-2P 689297-51-6P  
 689297-53-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)


RN 689296-91-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689296-94-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689296-98-8 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)




RN 689297-01-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2'-fluoro- (CA INDEX NAME)




RN 689297-04-9 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 689297-07-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-4'-fluoro- (CA INDEX NAME)




RN 689297-10-7 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 3'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-5'-fluoro- (CA INDEX NAME)




RN 689297-13-0 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2,2'-difluoro- (CA INDEX NAME)




RN 689297-15-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 7-ethyl-3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]- (CA INDEX NAME)




RN 689297-17-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6'-difluoro- (CA INDEX NAME)




RN 689297-19-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4'-difluoro- (CA INDEX NAME)




RN 689297-21-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7-(2,2-difluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-23-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-(1-methylethyl)-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-25-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[7-(2-fluoroethyl)-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)




RN 689297-27-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-29-8 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-7-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-8-oxoimidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-31-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-[7,8-dihydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]-2',4-difluoro- (CA INDEX NAME)




RN 689297-33-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)




RN 689297-35-6 CAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 3-chloro-5'-(7,8-dihydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)




RN 689297-37-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)




RN 689297-39-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8(7H)-one, 3-[4-fluoro-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]phenyl]-7-methyl- (CA INDEX NAME)




RN 689297-41-4 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)]- (CA INDEX NAME)




RN 689297-43-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',5-difluoro-5'-[(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)]- (CA INDEX NAME)




RN 689297-45-8 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-(5,6,7,8-tetrahydro-7-methyl-8-oxoimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)




RN 689297-47-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)




RN 689297-49-2 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',5-difluoro- (CA INDEX NAME)




RN 689297-51-6 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7-ethyl-5,6,7,8-tetrahydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',6-difluoro- (CA INDEX NAME)



RN 689297-53-8 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2',4-difluoro-5'-[5,6,7,8-tetrahydro-8-oxo-7-(2-pyridinylmethyl)imidazo[1,2-a]pyrazin-3-yl]- (CA INDEX NAME)




IT 689297-63-0P 689297-65-2P 689297-98-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyrazinone and imidazotriazinone derivs. as GABAA receptor ligands)


RN 689297-63-0 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)- (CA INDEX NAME)



RN 689297-65-2 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2'-fluoro- (CA INDEX NAME)



RN 689297-98-1 CAPLUS




CN [1,1'-Biphenyl]-2-carbonitrile, 5'-(7,8-dihydro-8-oxoimidazo[1,2-a]pyrazin-3-yl)-2',4-difluoro- (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1995:647967 CAPLUS  
 DOCUMENT NUMBER: 123:55918  
 TITLE: Preparation of 4-oxoimidazolo[1,2-a]quinoxalines as antagonists of excitatory amino acids.  
 INVENTOR(S): Treiber, Hans-Joerg; Behl, Berthold; Hofmann, Hans Peter  
 PATENT ASSIGNEE(S): BASF A.-G., Germany  
 SOURCE: Ger. Offen., 15 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4329970	A1	19941006	DE 1993-4329970	19930904
CA 2158167	A1	19941013	CA 1994-2158167	19940319
WO 9422865	A1	19941013	WO 1994-EP871	19940319
W: AU, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, NO, NZ, PL, RU, SI, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9464282	A	19941024	AU 1994-64282	19940319
BR 9406034	A	19960102	BR 1994-6034	19940319
EP 691970	A1	19960117	EP 1994-911932	19940319
EP 691970	B1	19981111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1120336	A	19960410	CN 1994-191613	19940319
CN 1041928	B	19990203		
JP 08508271	T	19960903	JP 1994-521617	19940319
HU 73970	A2	19961028	HU 1995-2848	19940319
AT 173263	T	19981115	AT 1994-911932	19940319
IL 109076	A	19970610	IL 1994-109076	19940322
ZA 9402246	A	19951002	ZA 1994-2246	19940330
FI 9504614	A	19950928	FI 1995-4614	19950928
NO 9503892	A	19950929	NO 1995-3892	19950929
PRIORITY APPLN. INFO.:				
			DE 1993-4310521	A1 19930331
			DE 1993-4329970	A 19930904
			WO 1994-EP871	W 19940319

OTHER SOURCE(S): MARPAT 123:55918  
 GI




I

- AB Title compds. [I; A = (unsatd.) C1-5 alkylene, bond; R1-R4 = H, F, Cl, Br, CF3, OCF3, cyano, NO2, amino, alkyl, alkoxy, alkylamino, alkylthio, alkylsulfenyl, alkylsulfonyl, aminosulfonyl, alkoxycarbonyl, etc.; R5 = H, alkyl, (substituted) Ph; R6 = CHO, (salt of) CO2H, CO2R7, hydroxyalkyl, alkylcarbonyl, cyano, tetrazolyl, aldoxime, carbamoyl, etc.; R7 = alkyl, cycloalkyl, PhCH2, etc.; with provisos], were prepared as antagonists of excitatory amino acids (no data). Thus, 1-(2-aminophenyl)-4-carboethoxy-5-methylimidazole was refluxed 1.5 h with carbonyldiimidazole in 1,2-dichlorobenzene to give Et 4,5-dihydro-1-methyl-4-oxoimidazolo[1,2-a]quinoxalin-2-carboxylate. Tablets were prepared containing 4,5-dihydro-1-methyl-7-(trifluoromethyl)-4-oxoimidazolo[1,2-a]quinoxalin-2-carboxylic acid.
- IT 164329-62-8P 164329-68-4P 164329-98-0P  
164330-04-5P 164330-31-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 4-oxoimidazolo[1,2-a]quinoxalines as antagonists of excitatory amino acids)
- RN 164329-62-8 CAPLUS
- CN Imidazo[1,2-a]quinoxaline-2-carboxylic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




- RN 164329-68-4 CAPLUS
- CN Imidazo[1,2-a]quinoxaline-2-propanoic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




RN 164329-98-0 CAPLUS

CN Imidazo[1,2-a]quinoxaline-2-carboxylic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)- (CA INDEX NAME)




RN 164330-04-5 CAPLUS

CN Imidazo[1,2-a]quinoxaline-2-propanoic acid, 4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)- (CA INDEX NAME)



RN 164330-31-8 CAPLUS

CN Imidazo[1,2-a]quinoxaline-2-propanoic acid, 8-chloro-4,5-dihydro-4-oxo-1-phenyl-7-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



ACCESSION NUMBER: 1959:72555 CAPLUS  
DOCUMENT NUMBER: 53:72555  
ORIGINAL REFERENCE NO.: 53:131391,13140a-i,13141a-f  
TITLE: Studies in the azole series. VII. Reactions of imidazoles with isocyanates  
AUTHOR(S): Gompper, Rudolf; Hoyer, Ernst; Herlinger, Heinz  
CORPORATE SOURCE: Tech. Hochschule, Stuttgart, Germany  
SOURCE: Chemische Berichte (1959), 92, 550-63  
CODEN: CHBEAM; ISSN: 0009-2940  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable

AB cf. C.A. 51, 13853i. 4,5-Disubstituted imidazoles containing at least 1 aryl group yield with boiling PhNCO in addition to the 4,5-disubstituted imidazole-2-carboxanilides and (PhNH)2CO (I) also 2-phenylimidazo[1,2-c]hydantoin which fluoresce in the solid state yellow to red depending on their color. Imidazoles react with aryl isocyanates in boiling PhNO2 to yield imidazole-2-carboxylic acid N-arylamides. The reaction mechanisms, the ultraviolet absorption, fluorescence, and infrared spectra of the various compds. are discussed. 4,5-Diphenylimidazole (II) (44 g.) and 250 cc. PhNCO refluxed 28 hrs., the excess PhNCO distilled in vacuo up to 170°, the yellow, resinous residue digested with C6H6, and the crystalline product recrystd. from 1:1 CHCl3-EtOAc yielded 31.5 g. anilide (III) of the 2-CO2H derivative (IV) of II, needles, m. 221-2°; the mother liquor deposited slowly 5 g. I, m. 240-2°; the C6H6 extract evaporated in vacuo, the semisolid residue digested with 400 cc. 1:1 MeOH-Et2O and filtered, and the filtrate evaporated gave 6 g. I; the filter residue recrystd. (EtOAc and then BuOH) gave 18.5 g. 2,5,6-triphenylimidazo[1,2-c]hydantoin (V), brilliant yellow needles, m. 207-8°. V (200 mg.) and 3 cc. PhNH2 refluxed 15 min., cooled 1 hr. to room temperature, and filtered yielded 95 mg. I; the mother liquor evaporated yielded 97 mg. III. V (17 g.), 132 g. KOH, 800 cc. MeOH, and 132 cc. H2O refluxed 0.5 hr., cooled overnight, and filtered, the residue dissolved in 300 cc. hot 15% HCl, the solution cooled, basified with aqueous NH4OH, and filtered, and the residue dissolved in hot glacial AcOH and stirred into H2O precipitated 6 g. IV, needles, m. 143-4° (decomposition) (30% aqueous EtOH). IV (1 g.) in 100 cc. absolute EtOH saturated with dry HCl, kept 3 days, poured into H2O, basified with NH4OH, and filtered gave 0.8 g. Et ester of IV, m. 197-200° (30% aqueous EtOH). IV (1.5 g.) refluxed 6 hrs. with 30 cc. SOCl2, kept overnight, and filtered gave 0.6 g. 2,3,7,8-tetraphenyl-5,10-dioxodimidazo[1,2-a;1',2'-d]piperazine (VI), yellow crystals, did not melt below 350° (PhNO2). VI (55 mg.) and 0.7 cc. PhNH2 heated 10 min., kept overnight, and the precipitate filtered off gave 60 mg. III. II (11 g.) in 100 cc. dry PhNO2 treated at 130° dropwise during 10 min. with 10 g. PhNCO and 10 cc. PhNO2, refluxed 9 hrs., and cooled gave 13.8 g. III, needles, m. 221-2° (EtOH). III (3.4 g.) and 2.6 g. Me2SO4 in 20 cc. PhNO2 heated 6 hrs. on the H2O bath, cooled, diluted with 250 cc. Et2O, and filtered, the residue shaken with a mixture of 100 cc. CHCl3 and 100 cc. 20% aqueous NaOH, and the CHCl3 layer worked up gave 1.8 g. 1-Me derivative (VII) of III, needles, m. 197-9° (EtOH). 1-Methyl-4,5-diphenylimidazole (8 g.) and 100 cc. PhNCO refluxed 16 hrs., the excess PhNCO distilled in vacuo, and the residue digested with EtOAc, filtered off, and recrystd. (EtOH) yielded 8.2 g. VII. 4(5)-Methyl-5(4)-phenylimidazole (VIII) (20 g.) and 170 cc. PhNCO refluxed 24 hrs., stored overnight, and filtered yielded 7 g. 5(6)-methyl-2,6(5)-diphenylimidazo[1,2-c]hydantoin (IX). pale yellow leaflets, m. 239-41° (BuOH). Et analog (8 g.) of VIII and 45 cc. PhNCO refluxed 20 hrs., the excess PhNCO distilled in vacuo, the residue dissolved in C6H6 and the solution filtered, the filtrate evaporated in vacuo, and the residue dissolved in EtOAc and allowed to evaporate in air gave 2.5 g. 5(6)-Et analog of IX, yellowish needles, m. 198-9° (BuOH).


p-Chlorobenzoin (20 g.) and 100 cc. HCONH<sub>2</sub> refluxed 4 hrs., kept overnight, and filtered, and the residue recrystd. [CH<sub>2</sub>(CO<sub>2</sub>Et)<sub>2</sub>] yielded 13 g. 4(5)-phenyl-5(4)-(p-chlorophenyl)imidazole (XI), m. 238-40°.

XI (10 g.) and 50 cc. PhNCO refluxed 22 hrs., the excess PhNCO distilled in vacuo, and the residue digested with C<sub>6</sub>H<sub>6</sub>, filtered off, and recrystd. (C<sub>6</sub>H<sub>6</sub>) yielded 6 g. 2-CONHPh derivative (XII) of XI, m. 192-4°; the C<sub>6</sub>H<sub>6</sub> solution evaporated and the residue crystallized from EtOAc gave 1.2 g. 2,5(6)-diphenyl-6(5)-(p-chlorophenyl)imidazo[1,2-c]hydantoin (XIII), m. 226-8° (BuOH). p-Bromobenzoin (17 g.) and 100 cc. HCONH<sub>2</sub> refluxed 4 hrs. and cooled, and the crude product recrystd. [CH<sub>2</sub>(CO<sub>2</sub>Et)<sub>2</sub>] yielded 9.2 g. p-Br analog (XIV) of XI, m. 240-2°. XIV (6 g.) and 50 cc. PhNCO heated 20 hrs. and evaporated, and the residue digested with 180 cc. C<sub>6</sub>H<sub>6</sub> left 1.5 g. p-Br analog of XII, needles, m. 181-3° (cyclohexane); the filtrate evaporated, the residue dissolved in EtOAc, the solution evaporated in air, the residue digested with iso-Pr<sub>2</sub>O, and the crude solid material recrystd. (BuOH) yielded 800 mg. p-Br analog of XIII, greenish yellow needles, m. 223-4°. 4(5)-Phenyl-5(4)-(p-dimethylaminophenyl)imidazole (15 g.) and 100 cc. PhNCO heated 23 hrs. and evaporated, and the residue digested with C<sub>6</sub>H<sub>6</sub>, filtered off, washed with C<sub>6</sub>H<sub>6</sub>, and recrystd. from PhMe yielded 8 g. p-Me<sub>2</sub>N analog of XII, needles, m. 208-9°; the C<sub>6</sub>H<sub>6</sub> filtrate evaporated and the residue crystallized (EtOAc) yielded 5.3 g. p-Me<sub>2</sub>N analog of XIII, brilliant red needles, m. 232-4° (BuOH). 1-Et derivative (XV) (4.3 g.) of II and 50 cc. PhNCO refluxed 16 hrs., the excess PhNCO evaporated in vacuo, the residue dissolved in 30 cc. EtOAc, the solution filtered, and the filtrate evaporated gave 3.5

- g. 2-CONHPh derivative of XV, leaflets, m. 141-3° (EtOH). II (20 g.) and 100 g. PhCH<sub>2</sub>Br heated 24 hrs. on the H<sub>2</sub>O bath and evaporated in vacuo, the resinous residue shaken with 250 cc. 20% aqueous NaOH and 200 cc. CHCl<sub>3</sub>, the CHCl<sub>3</sub> layer evaporated, the residue dissolved in hot EtOH, the hot solution diluted with hot H<sub>2</sub>O to incipient turbidity, cooled, and filtered, the filtrate diluted further with H<sub>2</sub>O, the tacky precipitate dissolved in CHCl<sub>3</sub>, and the solution diluted with Et<sub>2</sub>O to turbidity and refrigerated several days gave 3.6 g. 4,5-diphenyl-1,3-dibenzyl-imidazolium bromide (XVI), leaflets, m. 211-13° [CH<sub>2</sub>(CO<sub>2</sub>Et)<sub>2</sub>]. XVI (3 g.) and 30 cc. PhNCO refluxed 16 hrs. and evaporated gave 2.1 g. 1-PhCH<sub>2</sub> derivative of III, needles, m. 160-1° (EtOAc); also obtained from the 1-PhCH<sub>2</sub> derivative of II with PhNCO. II (7 g.) and 5 g. p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NCO refluxed 6 hrs. in 50 cc. PhNO<sub>2</sub>, cooled overnight, and filtered yielded 9 g. p-nitroanilide of IV, yellow leaflets, m. 316-19° (PhNO<sub>2</sub>). II (4.4 g.) dissolved in 40 cc. PhNO<sub>2</sub> at 100°, treated during 10 min. dropwise with 5 g. 1-ClOH<sup>+</sup>7NCO (XVII), refluxed 6 hrs., stored 3 days, and filtered yielded 5.8 g. 1-naphthylamide (XVIII) of IV, needles, m. 239-41° (1:1 CHCl<sub>3</sub>:EtOAc). 1-Me derivative (3 g.) of II and 5 g. XVII in 50 cc. PhNO<sub>2</sub> refluxed 6 hrs. and evaporated gave 2.9 g. 1-Me derivative of XVIII, needles, m. 180-1° (EtOH). 3-Phenylindole (5 g.) and 50 cc. PhNCO refluxed 20 hrs. and evaporated in vacuo, and the residue digested with C<sub>6</sub>H<sub>6</sub> and the solution filtered gave 6 g. 3-phenylindole-2-carboxanilide, needles, m. 116-18° (EtOH or cyclohexane). 2,4-Diphenylpyrrole (4.4 g.) and 40 cc. PhNCO refluxed 20 hrs. and evaporated in vacuo gave 3.8 g. yellow needles, m. 165° (C<sub>6</sub>H<sub>6</sub>), apparently containing a hydantoin ring. 2-Methyl-4(5)-phenylimidazole (XIX) (5 g.) and 7.5 cc. PhNCO refluxed 9 hrs. in 65 cc. PhNO<sub>2</sub>, cooled, and filtered gave 4 g. 5(4)-CONHPh derivative of XIX, needles, m. 240-2° (decomposition) (EtOH). Benzimidazole (6 g.) and 10 cc. PhNCO in 100 cc. PhNO<sub>2</sub> refluxed 5 hrs. and worked up in the usual manner yielded 5.5 g. benzimidazole-2-carboxanilide, needles, m. 235-6°. Theophylline (20 g.) and 36 g. PhNCO refluxed to solution, cooled, and filtered, and the residue boiled briefly with EtOH yielded 30

g. theophylline-7(9)-carboxanilide, m. 208° with gas evolution at 215-18°, resolidified at 220°, and remelted at 265° (theophylline). II (2 g.) and 3.5 cc. PhNCO allowed to stand 12 hrs. and filtered, and the residue washed with C6H6 gave 3 g. 1-CONHPh derivative of II, m. partially at about 115° (decomposition) (melt clear at 230°); the attempted recrystn. from C6H6 or PhMe gave only II. The ultraviolet, fluorescence, and infrared absorption maximum of the various compds. are tabulated.

IT 119925-84-7P, 5H,10H-Diimidazo[1,2-a:1',2'-d]pyrazine-5,10-dione,  
2,3,7,8-tetraphenyl-  
RL: PREP (Preparation)  
(preparation of)  
RN 119925-84-7 CAPLUS  
CN 5H,10H-Diimidazo[1,2-a:1',2'-d]pyrazine-5,10-dione, 2,3,7,8-tetraphenyl-  
(CA INDEX NAME)



=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
47.44	226.47

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-6.40	-6.40

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 16:45:04 ON 12 MAR 2008